Elanco Animal Health Inc. (ELAN) announced the U.S. Food and Drug Administration has approved Zenrelia, a convenient once-daily oral ...

Zenrelia is one of several drugs Elanco has in its pipeline that it predicts could reach blockbuster status, which in animal ...

U.S. Food and Drug Administration approves Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and atopic ...

The FDA announced earlier today that ilunocitinib tablets (Zenrelia; Elanco) has received its approval. The latest drug from ...

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

The U.S. Food and Drug Administration has approved Elanco Animal Health's skin disease treatment for dogs, the health ...

In addition to presenting 30 abstracts with data on prurigo nodularis, atopic dermatitis, sensitive skin and acne, Galderma will host a series of events dedicated to addressing the real needs of ...

U.S. Food and Drug Administration approves Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and atopic ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has commenced its Phase 2a clinical trial for ATI-2138, an innovative oral covalent ...

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.